Achieve Life Sciences, Inc. (ACHV)

Market Cap	154.48M
Revenue (ttm)	n/a
Net Income (ttm)	-29.82M
Shares Out	34.25M
EPS (ttm)	-1.50
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	35,370
Open	4.550
Previous Close	4.570
Day's Range	4.430 - 4.619
52-Week Range	3.030 - 10.300
Beta	1.28
Analysts	Strong Buy
Price Target	16.33 (+262.08%)
Earnings Date	May 7, 2024

About ACHV

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc. is based in Vancouver, Canada.

• Industry: Biotechnology
• Sector: Healthcare
• CEO: John A. Bencich M.B.A.
• Employees: 22
• Stock Exchange: NASDAQ
• Ticker Symbol: ACHV

Analyst Forecast

According to 3 analysts, the average rating for ACHV stock is "Strong Buy." The 12-month stock price forecast is $16.33, which is an increase of 262.08% from the latest price.

Price Target

$16.33

(262.08% upside)

Analyst Consensus: Strong Buy